The United States filed a complaint under the False Claims Act (FCA) against Regeneron Pharmaceuticals Inc. (Regeneron), a New York-based pharmaceutical company. Regeneron manufactures and sells Eylea, an anti-vascular endothelial growth factor inhibitor approved by the Food and Drug Administration to treat, among other conditions, neovascular Age-Related Macular Degeneration, a prevalent, usually age-related condition that impairs vision. Read More
Home » False Claims Act Complaint Filed Against Regeneron Pharmaceuticals for Fraudulent Drug Pricing Reporting
False Claims Act Complaint Filed Against Regeneron Pharmaceuticals for Fraudulent Drug Pricing Reporting
Related Posts
Iranian National Indicted for Operating Online Marketplace Offering Fentanyl and Money Laundering Services
A federal grand jury has charged Behrouz Parsarad, an Iranian national, for his role as the founder and operator of Nemesis Market, a dark web… BronIranian National Indicted for Operating Online Marketplace Offering Fentanyl and Money Laundering Services
MS-13 Member Sentenced to Over 12 Years for Kidnapping, Witness
An MS-13 member and Honduran national, illegally in the United States, was sentenced today to 147 months in prison for kidnapping, retaliating against a federal… BronMS-13 Member Sentenced to Over 12 Years for Kidnapping, Witness
United States Files Complaint Against Barco Uniforms and Its
The United States has filed a complaint against Barco Uniforms Inc. (Barco), Kenny Chan, David Chan, and companies operated and controlled by the Chans, alleging that… BronUnited States Files Complaint Against Barco Uniforms and Its